Cargando…

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via...

Descripción completa

Detalles Bibliográficos
Autores principales: Morioka, S., Tsuzuki, S., Suzuki, M., Terada, M., Akashi, M., Osanai, Y., Kuge, C., Sanada, M., Tanaka, K., Maruki, T., Takahashi, K., Saito, S., Hayakawa, K., Teruya, K., Hojo, M., Ohmagari, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365517/
https://www.ncbi.nlm.nih.gov/pubmed/35963600
http://dx.doi.org/10.1016/j.jiac.2022.08.007
_version_ 1784765355106762752
author Morioka, S.
Tsuzuki, S.
Suzuki, M.
Terada, M.
Akashi, M.
Osanai, Y.
Kuge, C.
Sanada, M.
Tanaka, K.
Maruki, T.
Takahashi, K.
Saito, S.
Hayakawa, K.
Teruya, K.
Hojo, M.
Ohmagari, N.
author_facet Morioka, S.
Tsuzuki, S.
Suzuki, M.
Terada, M.
Akashi, M.
Osanai, Y.
Kuge, C.
Sanada, M.
Tanaka, K.
Maruki, T.
Takahashi, K.
Saito, S.
Hayakawa, K.
Teruya, K.
Hojo, M.
Ohmagari, N.
author_sort Morioka, S.
collection PubMed
description OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. RESULTS: We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively. CONCLUSIONS: The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.
format Online
Article
Text
id pubmed-9365517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93655172022-08-11 Post COVID-19 condition of the Omicron variant of SARS-CoV-2 Morioka, S. Tsuzuki, S. Suzuki, M. Terada, M. Akashi, M. Osanai, Y. Kuge, C. Sanada, M. Tanaka, K. Maruki, T. Takahashi, K. Saito, S. Hayakawa, K. Teruya, K. Hojo, M. Ohmagari, N. J Infect Chemother Original Article OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. RESULTS: We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively. CONCLUSIONS: The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-11 2022-08-11 /pmc/articles/PMC9365517/ /pubmed/35963600 http://dx.doi.org/10.1016/j.jiac.2022.08.007 Text en © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Morioka, S.
Tsuzuki, S.
Suzuki, M.
Terada, M.
Akashi, M.
Osanai, Y.
Kuge, C.
Sanada, M.
Tanaka, K.
Maruki, T.
Takahashi, K.
Saito, S.
Hayakawa, K.
Teruya, K.
Hojo, M.
Ohmagari, N.
Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title_full Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title_fullStr Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title_full_unstemmed Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title_short Post COVID-19 condition of the Omicron variant of SARS-CoV-2
title_sort post covid-19 condition of the omicron variant of sars-cov-2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365517/
https://www.ncbi.nlm.nih.gov/pubmed/35963600
http://dx.doi.org/10.1016/j.jiac.2022.08.007
work_keys_str_mv AT moriokas postcovid19conditionoftheomicronvariantofsarscov2
AT tsuzukis postcovid19conditionoftheomicronvariantofsarscov2
AT suzukim postcovid19conditionoftheomicronvariantofsarscov2
AT teradam postcovid19conditionoftheomicronvariantofsarscov2
AT akashim postcovid19conditionoftheomicronvariantofsarscov2
AT osanaiy postcovid19conditionoftheomicronvariantofsarscov2
AT kugec postcovid19conditionoftheomicronvariantofsarscov2
AT sanadam postcovid19conditionoftheomicronvariantofsarscov2
AT tanakak postcovid19conditionoftheomicronvariantofsarscov2
AT marukit postcovid19conditionoftheomicronvariantofsarscov2
AT takahashik postcovid19conditionoftheomicronvariantofsarscov2
AT saitos postcovid19conditionoftheomicronvariantofsarscov2
AT hayakawak postcovid19conditionoftheomicronvariantofsarscov2
AT teruyak postcovid19conditionoftheomicronvariantofsarscov2
AT hojom postcovid19conditionoftheomicronvariantofsarscov2
AT ohmagarin postcovid19conditionoftheomicronvariantofsarscov2